Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain

NEW YORK AND INDIANAPOLIS, March 25, 2021—Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced the outcome of the U.S. Food and Drug Administration (FDA) Joint Arthritis Advisory Committee and Drug Safety and Risk...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news